http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2534199-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 |
| filingDate | 2009-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3ce49d0fb29a3450ba7989a65f26c1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579f5f8b7d58572f3579ae91985e9994 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6294e7b9e4fdfc2fbbf2e527660de65c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99c87c1ac5471b3a029d6d926f6a8171 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ac1a6121cec5fee3422e9ff7f28e559 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed33393e3e111c1550a835045499bd66 |
| publicationDate | 2015-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2534199-T3 |
| titleOfInvention | P2X3 receptor antagonists for pain management |
| abstract | A compound of structural formula I: ** Formula ** or pharmaceutically acceptable salts and individual enantiomers and diastereomers thereof in which: X is N or CH; W and Z independently, are absent or represent C (R2) 2, -O-, NR2, CO or SO0-2; R1 represents H, C1-6 alkyl, halogen, (CH2) nCF3, C3-10 cycloalkyl, C (R2) 2OH, -O-, CN, (CH2) nOR210, (CH2) n C5-10 heterocyclic, aryl (CH2 ) nC6-10 or C1-6 alkoxy; said alkyl, cycloalkyl, heterocyclyl and aryl being optionally substituted with 1 to 3 C1-6 alkyl groups, halogen, hydroxyl, (CH2) nCF3 or CN; R2 represents H, C1-6 alkyl, CF3, OH, CHF2 or CH2F; R3 represents CR2R4R5; one of R4 and R5 is C1-6 alkyl or hydrogen and the other is (CH2) C6-10 naryl or (CH2) C6-10 nheterocyclyl, said alkyl, aryl and heterocyclyl being optionally substituted with 1 to 3 groups of Ra, in wherein said aryl and heterocyclyl are (CH2) n phenyl, (CH2) npyridyl, (CH2) npyrimidinyl, (CH2) ntriazolyl, pyrazinyl or (CH2) noxadiazolyl; R6 represents hydrogen, OR2, -O-, CF3, C (R2) 2OR2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, (CH2) C6-10 naryl, (CH2) nheterocyclyl C5-10, said alkyl, aryl and heterocyclyl being optionally substituted with 1 to 3 groups of Ra20; Ra represents C1-6 alkyl, halogen, hydroxyl, OR2 (CH2) nCF3, -O-, C3-6 cycloalkyl, NR2C (O) R2, C (O) N (R2) 2, C (R2) 2OR2, C ( O) R2 NO2, CN, N (R2) 2, C (O) OR2, SO2R2, OR2, (CH2) C5-10 nheterocyclyl or (CH2) C6-10 naryl, said heterocyclyl and aryl being optionally substituted with 1 to 3 C1-6 alkyl, halogen, hydroxyl, (CH2) nCF3 or CN groups; and n represents from 0 to 4. |
| priorityDate | 2008-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 487.